/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Pliant Therapeutics Inc Share Price Today: Live Updates & Key Insights

Pliant Therapeutics Inc share price today is $1.41, up 6.02%. The stock opened at $1.34 against the previous close of $1.33, with an intraday high of $1.42 and low of $1.335.

Pliant Therapeutics Inc Share Price Chart

style
pb-0

Pliant Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Pliant Therapeutics Inc Share Price Performance

$1.41 0.0602(6.02%) PLRX at 13 Mar 2026 02:47 PM Biotechnology
Lowest Today 1.335
Highest Today 1.42
Today’s Open 1.34
Prev. Close 1.33
52 Week High 1.95
52 Week Low 1.09
Day’s Range: Low 1.335 High 1.42
52-Week Range: Low 1.09 High 1.95
1 day return -
1 Week return +6.39
1 month return +26.33
3 month return +13.65
6 month return -6.9
1 year return -7.21
3 year return -94.99
5 year return -96.29
10 year return -

Pliant Therapeutics Inc Institutional Holdings

TANG CAPITAL MANAGEMENT LLC 9.77

Point72 Asset Management, L.P. 7.06

JPMorgan Chase & Co 6.93

Morgan Stanley - Brokerage Accounts 5.71

Blue Owl Capital Holdings LP 4.83

Vanguard Group Inc 4.59

Acadian Asset Management LLC 3.86

Citadel Advisors Llc 3.81

Woodline Partners LP 3.30

Vanguard Total Stock Mkt Idx Inv 2.84

Redmile Group, LLC 2.59

Prosight Management, LP 2.53

BML Capital Management LLC 2.52

BlackRock Inc 2.31

UBS Group AG 2.15

Two Sigma Advisers, LLC 2.03

Renaissance Technologies Corp 1.70

Centiva Capital LP 1.63

Two Sigma Investments LLC 1.55

Peapod Lane Capital LLC 1.44

Great Point Partners LLC 1.38

Vanguard Institutional Extnd Mkt Idx Tr 0.91

Sun Life Global Mid Cap Fund I 0.61

Bridgeway Ultra-Small Company 0.39

Fidelity Extended Market Index 0.32

iShares Micro-Cap ETF 0.24

Blackrock Extended Mkt Fund CF 0.20

Vanguard Health Care ETF 0.19

Invesco RAFI US 1500 Small-Mid ETF 0.19

Extended Equity Market Fund K 0.17

Fidelity Total Market Index 0.15

Bridgeway Ultra-Small Company Market 0.13

Fidelity Series Total Market Index 0.12

Spartan Extended Market Index Pool F 0.12

Northern Trust Extended Eq Market Idx 0.10

NT Ext Equity Mkt Idx Fd - L 0.08

Vanguard Instl Ttl Stck Mkt Idx Tr 0.07

Spartan Total Market Index Pool G 0.07

NT Ext Equity Mkt Idx Fd - NL 0.07

Vanguard Balanced Index Inv 0.06

Pliant Therapeutics Inc Market Status

Strong Buy: 1

Buy: 1

Hold: 11

Sell: 0

Strong Sell: 0

Pliant Therapeutics Inc Fundamentals

Market Cap 81.73 M

PB Ratio 0.408

PE Ratio 0.0

Enterprise Value -100.21 M

Total Assets 225.23 M

Volume 1202826

Pliant Therapeutics Inc Company Financials

Annual Revenue FY23:3545000 3.5M, FY22:9685000 9.7M, FY21:7572000 7.6M, FY20:41817000 41.8M, FY19:57052000 57.1M

Annual Profit FY23:null 0.0M, FY22:9685000 9.7M, FY21:7572000 7.6M, FY20:41817000 41.8M, FY19:57052000 57.1M

Annual Net worth FY23:-155287000 -155.3M, FY22:-121498000 -121.5M, FY21:-17907000 -17.9M, FY20:-39745000 -39.7M, FY19:185000 0.2M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-447000 -0.4M, Q1/2025:-448000 -0.4M, Q3/2024:null 0.0M, Q2/2024:-622000 -0.6M

Quarterly Net worth Q3/2025:-26301000 -26.3M, Q2/2025:-43300000 -43.3M, Q1/2025:-56166000 -56.2M, Q3/2024:-57763000 -57.8M, Q2/2024:-55854000 -55.9M

About Pliant Therapeutics Inc & investment objective

Company Information Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 171

Industry Biotechnology

CEO Dr. Bernard Coulie M.B.A., M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow